Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Sylatron in advanced cholangiocarcinoma
NCT02982720Phase 2Terminated
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of peginterferon alfa-2b in cholangiocarcinoma (CCA). Started Jul 2017; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02982720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982720.